Travere Therapeutics (TVTX) Free Cash Flow (2011 - 2026)
Travere Therapeutics' (TVTX) quarterly Free Cash Flow came in at -$40.4 million in Q1 2026, up 4.33% YoY from -$38.7 million in Q1 2025, and down 166.52% on a QoQ basis from $60.7 million in Q4 2025.
Travere Therapeutics (TVTX) Free Cash Flow (2011 - 2026) Analysis & Trends
Travere Therapeutics (TVTX) has 16 years of Free Cash Flow data on file, last reported at -$40.4 million in Q1 2026.
- Quarterly Free Cash Flow rose 4.33% year-over-year to -$40.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $39.5 million (up 124.54% YoY) and the FY2025 annual result came in at $37.8 million, up 115.91% from the prior year.
- Free Cash Flow retreated to -$40.4 million in Q1 2026, from $60.7 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $60.7 million in Q4 2025 to a low of -$118.9 million in Q1 2024.
- A 5-year average of -$44.3 million and a median of -$42.1 million in 2024 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow sank 675.99% — and 2025, when it surged 268.17%.
- Tracing TVTX's Free Cash Flow over 5 years: stood at -$54.7 million in 2022, then tumbled by 111.88% to -$115.8 million in 2023, then soared by 68.85% to -$36.1 million in 2024, then surged by 268.17% to $60.7 million in 2025, then sank by 166.52% to -$40.4 million in 2026.
- The last three Free Cash Flow figures came in at -$40.4 million (Q1 2026), $60.7 million (Q4 2025), and $14.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn | 58.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 58.07 Mn |
| Jun 30, 2026 | 58.07 Mn |
| Mar 31, 2026 | -40.37 Mn |
| Mar 31, 2026 | -40.37 Mn |
| Dec 31, 2025 | 60.68 Mn |
| Dec 31, 2025 | 60.68 Mn |
| Sep 30, 2025 | 14.18 Mn |
| Sep 30, 2025 | 14.18 Mn |
| Jun 30, 2025 | 4.98 Mn |
| Jun 30, 2025 | 4.98 Mn |
| Mar 31, 2025 | -42.19 Mn |
| Mar 31, 2025 | -42.19 Mn |
| Dec 31, 2024 | -36.08 Mn |
| Dec 31, 2024 | -36.08 Mn |
| Sep 30, 2024 | -42.15 Mn |
| Sep 30, 2024 | -42.15 Mn |
| Jun 30, 2024 | -40.43 Mn |
| Jun 30, 2024 | -40.43 Mn |
| Mar 31, 2024 | -118.90 Mn |
| Mar 31, 2024 | -118.90 Mn |